This potential TIL restriction of fingolimod is supported by a previous study, which found that fingolimod reduced the recirculation of CD8+ effector T cells and their recruitment to peripheral lesions in a mouse model of diabetes [17]. Here, CD8A is linked to diabetes mellitus.